R & D

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

 This material is intended to notify the press release issued on February 13 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click  https://www.bms.com/media/press-releases.html  for the original press release.